News
News
Why IFIGENEIA Matters: Centre for Research and Technology Hellas
What makes IFIGENEIA important for the Centre for Research and Technology Hellas (CERTH)? Nikolaos Laloumis shares how participating in the project strengthens CERTH's commitment to scientific excellence, innovation and international cooperation. Hear their...
Can particle accelerators help reduce Cadmium in raspberries?
Twenty-four students from across Europe gathered at the Faculty of Science of the University of Sarajevo for a challenge on the use of particle accelerators to address societal applications in the Balkans. These young physicists, engineers, chemists, and life...
Did you know: Targeted radionuclide therapy isn’t just for humans
Did you know that targeted radionuclide therapy is used not only to treat people but also animals? When we think about radiation therapy, we usually imagine hospitals treating cancer patients. But the same science is also helping veterinarians treat diseases in pets....
IFIGENEIA Releases Its Third Newsletter
The IFIGENEIA project has published the third edition of its newsletter, reflecting on the progress achieved during the first project year and looking ahead to the next phase of scientific, technical and collaborative activities. This edition highlights IFIGENEIA’s...
IFIGENEIA Workshop: Low Energy Accelerators
In the framework of the IFIGENEIA mentorship activities, an International Workshop will take place in Sarajevo, Bosnia and Herzegovina, hosted by UNSA, from 22 to 24 September 2026, on Particle Accelerators Applications for Society. Expert lectures will cover...
From Curiosity to Innovation: My Journey to Sarajevo
On 17 September 2026, the online lecture series of the Challenge Based Innovation CBI2026 special edition, focusing on Particle Accelerators’ Applications for Society (https://indico.cern.ch/event/1661135/page/42417-challenge-based-innovation), concluded with a...
CBI2026: Students Explore Particle Accelerator Applications for Society
The Challenge Based Innovation 2026 programme began online on 1 September. Through introductory lectures, participating students are learning about particle accelerators and exploring how these technologies could benefit society. From online learning to Sarajevo The...
Lu-177 Therapies: Rising Future Demand
Demand for Lu-177-based cancer therapies is expected to grow significantly across Europe and the wider region by 2040, according to recent analytical work carried out within the IFIGENEIA project, covering Cyprus, Slovenia, Greece, Croatia and North Macedonia. The...
One Technology, Two Worlds: Art and Medicine
The European project IFIGENEIA is developing technologies and expertise for accelerator-based applications in nuclear medicine. As part of the project’s knowledge-transfer and capacity-building activities, accelerator-based techniques are also being explored for...
Did you know: Iodine-131: A small atom with a big history
The story of iodine-131 began in the late 1930s, when physicists at MIT - including Saul Hertz and Arthur Roberts - first proposed that radioactive iodine could be used to treat thyroid disease. Their insight was elegant: the thyroid gland naturally absorbs iodine...
Why IFIGENEIA Matters: YFOS
What does IFIGENEIA mean to YFOS? In this one-minute video, Theano Lampoudi shares what motivated YFOS to join the project and how IFIGENEIA supports the company's vision for innovation and technological advancement. Watch the video to hear their story.
Medical Radioisotopes Innovation in Central Macedonia
Advancing innovation in nuclear medicine, strengthening research capacity, and fostering collaboration across the health ecosystem are among the key opportunities highlighted through ongoing efforts to develop radioisotope production capabilities in Central Macedonia....